Radioimmunoluminography: a Tool for Relating Tissue Antigen Concentration to Clinical Outcome

Overview

Journal Br J Cancer

Specialty Oncology

Date 1999 Jun 9

PMID 10360677

Citations 1

Authors

G Boxer

A Flynn

A Green

R Begent

Affiliations

Soon will be listed here.

Abstract

Proteins control cell function and measurement of their concentration is crucial for understanding their roles in health and disease. However, current methods for their detection in tissue sections are not quantitative. Radioimmunoluminography (RILG) is a system for direct measurement of quantity and distribution of protein in histological sections. Histological carcinomas were reacted with antigen-saturating concentrations of 125I-antibody to carcinoembryonic antigen (CEA). Antibody distribution and concentration was mapped by phosphor imaging. Radioactivity in each pixel of the digital image was proportional to antigen concentration, calculated from a standard line generated from a nitrocellulose CEA dot-blot assay. RILG gave a linear correlation with standards of known CEA concentration (r = 0.999). Six tumour xenografts with differing CEA concentrations by radioimmunoassay (RIA) were studied by RILG and immunohistochemistry (IHC). RILG gave a linear correlation with CEA by RIA (r = 0.994) but IHC failed to do so (r = 0.42). CEA levels measured by RILG, in cryostat (n = 15) and paraffin (n = 19) sections from colorectal cancer patients showed a range of CEA concentration (38.9-594 ng g(-1) and 22.5-212.5 ng g(-1) respectively). Tumour CEA concentration by RILG was significantly correlated with dose of antibody (% injected radioactivity kg(-1)) localized in tumour (P = 0.04 and P < 0.02 respectively), in patients receiving radioimmunoguided surgery. Clinical relevance of RILG is illustrated by identifying patients with high tumour CEA, most likely to benefit from antibody targeted therapy. Knowledge of the pathophysiology of many diseases may be enhanced by quantitative estimation of antigen concentration related to tissue morphology.

Citing Articles

Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.

Ibanez-Perez R, Guerrero-Ochoa P, Al-Wasaby S, Navarro R, Tapia-Galisteo A, de Miguel D Oncoimmunology. 2019; 8(11):1641392.

PMID: 31646080 PMC: 6791445. DOI: 10.1080/2162402X.2019.1641392.

References

Fraker P, SPECK Jr J . Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. 1978; 80(4):849-57. DOI: 10.1016/0006-291x(78)91322-0. View

Poznansky M, Juliano R . Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev. 1984; 36(4):277-336. View

Pedley R, Boden J, Boden R, Boxer G, Flynn A, Keep P . Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 1996; 56(14):3293-300. View

Marshall D, Pedley R, Melton R, Boden J, Boden R, Begent R . Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody. Br J Cancer. 1995; 71(1):18-24. PMC: 2033472. DOI: 10.1038/bjc.1995.5. View

Okuyama M, HATORI Y, Shigematsu A . Autoradioluminography, a novel quantitative method of TLC-autoradiography. Biol Pharm Bull. 1994; 17(5):559-63. DOI: 10.1248/bpb.17.559. View

Lane D, Eagle K, Begent R, Green A, Casey J, Keep P . Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer. 1994; 70(3):521-5. PMC: 2033373. DOI: 10.1038/bjc.1994.338. View

Chung J, Jang J, Lee D, Lee M, Koh C . Tumor concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography. J Nucl Med. 1994; 35(9):1499-505. View

Boxer G, Begent R, Kelly A, Southall P, Blair S, Theodorou N . Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy. Br J Cancer. 1992; 65(6):825-31. PMC: 1977772. DOI: 10.1038/bjc.1992.176. View

Shockley T, Lin K, Nagy J, Tompkins R, Dvorak H, Yarmush M . Penetration of tumor tissue by antibodies and other immunoproteins. Ann N Y Acad Sci. 1991; 618:367-82. DOI: 10.1111/j.1749-6632.1991.tb27257.x. View

10.

Blair S, Theodorou N, Begent R, Dawson P, Salmon M, Riggs S . Comparison of anti-fetal colonic microvillus and anti-CEA antibodies in peroperative radioimmunolocalisation of colorectal cancer. Br J Cancer. 1990; 61(6):891-4. PMC: 1971674. DOI: 10.1038/bjc.1990.199. View

11.

Southall P, Boxer G, Bagshawe K, Hole N, Bromley M, Stern P . Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990; 61(1):89-95. PMC: 1971328. DOI: 10.1038/bjc.1990.20. View

12.

Hitchins R, Begent R, Green A, Searle F, Van Heyningen V, Bagshawe K . Clinical value of imaging using antibody to alpha fetoprotein in germ cell tumours. Nuklearmedizin. 1989; 28(1):29-33. View

13.

Jain R . Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst. 1989; 81(8):570-6. DOI: 10.1093/jnci/81.8.570. View

14.

Harwood P, Britton D, Southall P, Boxer G, Rawlins G, Rogers G . Mapping epitope characteristics on carcinoembryonic antigen. Br J Cancer. 1986; 54(1):75-82. PMC: 2001645. DOI: 10.1038/bjc.1986.154. View